Form 4: Jazz Pharmaceuticals Executive Robert Iannone Reports Share Transactions Following Performance Vesting

Robert Iannone, EVP, G R&D and CMO of Jazz Pharmaceuticals, reports the acquisition of 7,506 ordinary shares and the disposal of 2,181 shares to cover tax obligations following the vesting of performance share awards.

Summary

• Robert Iannone, an executive at Jazz Pharmaceuticals, reported transactions involving the company's ordinary shares.
• On January 17, 2025, 7,506 ordinary shares were acquired due to the vesting of performance share awards granted on March 3, 2022.
• The performance-based vesting requirements were met and certified on January 17, 2025.
• Additionally, 2,181 shares were disposed of on the same date to cover tax obligations related to the vesting.
• The executive also acquired 167 ordinary shares on May 31, 2024 and 48 ordinary shares on November 29, 2024 through an Employee Stock Purchase Plan.
• Following these transactions, Iannone beneficially owns 67,766 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive share transactions following the vesting of performance awards. It is a neutral event with a slightly positive sentiment due to the achievement of performance goals.

Positives

• The vesting of performance share awards indicates that performance goals were met, which is a positive sign for the company.
• The acquisition of shares through the Employee Stock Purchase Plan shows the executive's continued investment in the company.

Negatives

• The disposal of 2,181 shares to cover tax obligations, while standard, reduces the executive's overall shareholding.

Risks

• There are no specific risks mentioned in this document, as it primarily reports share transactions.

Industry Context

This is a standard SEC Form 4 filing, which is common for executives of publicly traded companies. It reflects the normal course of share-based compensation and tax obligations.

Comparison to Industry Standards

• Share-based compensation is a common practice in the pharmaceutical industry, used to align executive interests with company performance.
• Vesting schedules and tax withholding are standard procedures for equity awards.
• Other pharmaceutical companies such as AbbVie, Amgen, and Gilead Sciences also regularly report similar transactions by their executives.

Stakeholder Impact

• The share transactions have a minor impact on shareholders, as they reflect the normal course of executive compensation.
• The vesting of performance awards may be viewed positively by shareholders as it indicates the achievement of company goals.

Key Dates

Keywords

Jazz Pharmaceuticals, Robert Iannone, share transactions, performance share awards, vesting, employee stock purchase plan, insider trading, beneficial ownership